US based medical device company Veran Medical Technologies has reported results from the initial study of its SPiNPerc procedure.

Image

According to Veran Medical Technologies, the SPiNPerc endobronchial percutaneous biopsy study results support the use of a percutaneous approach to biopsy when a traditional bronchoscopic method is not possible.

Final results for the initial study of SPiNPerc procedure showed a hospital savings of $693,327 per 200 lung cancer screening patients with positive findings.

The Lung Cancer Management study was written by thoracic surgeon and expert in the SPiNPerc procedure Dr Adam Lee.

The practice points conclude that having both navigation bronchoscopy and computed tomography fine-needle aspiration ready on the same platform allows an easy transition from one procedure to the other if the first approach fails.

Dr Lee said: "Besides the cost effectiveness of SPiNPerc, Veran’s technology gives me every tool I need to diagnosis and treat my patient in the best way, which demonstrates the practice of good medicine."

Veran Medical Technologies marketing global vice president Rob Powers said that ENB has been on the market for nearly ten years and the five-year survival rate remains an unacceptable 15-16%.

"We are providing both an advanced ENB system and innovations like SPiNPerc that have the potential to impact survival, Powers added.

"Setting up a comprehensive lung cancer screening program is important. The SPiNPerc procedure clearly offers a cost effective new patient care pathway for those patients with a suspicious lesion found on their CT scan."

Currently, a SPiNPerc clinical trial is in process at Johns Hopkins Hospital in Baltimore, Maryland, in addition to the SPiNPerc endobronchial percutaneous biopsy study. An interim analysis has shown the procedure to be feasible and safe with final data to be published soon.


Image: Veran Medical Technologies’ SPiNView system. Photo: Courtesy of PRNewsWire/ Veran Medical Technologies